A Phase 2 interventional study of Trastuzumab deruxtecan in Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast, sponsored by AstraZeneca. Active, not recruiting at 30 sites in 9 countries. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-03-23.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing trastuzumab deruxtecan in Neoplasm Metastasis — 10 open to participants now, 13 under way, 2 of them phase 3. trastuzumab deruxtecan · Neoplasm Metastasis.
Among the 20 studies testing trastuzumab deruxtecan in Neoplasm Metastasis, this one is the 7th largest by enrollment, is one of 3 that started in 2020, is one of 11 in phase 2, reaches primary completion later than 0 of the 12 other live ones, and was the 10th registered.
4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.
Browse Neoplasm Metastasis studies →10 of the 20 studies testing trastuzumab deruxtecan in Neoplasm Metastasis are open now, in 12 countries. Recruiting first, the newest first:
Gruppo Oncologico del Nord-Ovest · Sites in France, Germany, Italy and 1 more country
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Daiichi Sankyo · Sites in United States, Australia, Brazil and 10 more countries
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
By country, each count listing its studies:
trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.
This study: 18 Years to 120 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab deruxtecan is the treatment under test here. Read study by study →
20 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is above the median of 50 across 3,271 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 69 across the 20 interventional studies. Of the 7 that completed or were terminated, 7 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 20 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
60 studies in Neoplasm Metastasis by AstraZeneca: 6 open now, 23 under way, 14 of them phase 3. Of 36 finished, 16 (44%) have results posted.
Among the 60 studies in Neoplasm Metastasis by AstraZeneca, this one is the 28th largest by enrollment of the 55 interventional ones that give a count, is one of 3 that started in 2020, is one of 13 in phase 2, reaches primary completion later than 5 of the 22 other live ones, and was the 44th registered.
AstraZeneca’s Neoplasm Metastasis studies by the year they started, since 1998.
4 of the studies testing trastuzumab deruxtecan in Neoplasm Metastasis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT04585958National Cancer Institute (NCI)Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer | 2026-12-31 |
| NCT06058988Memorial Sloan Kettering Cancer CenterTrastuzumab Deruxtecan (T-DXd) for People With Brain Cancer | 2027-09-22 |
| NCT07407465Gruppo Oncologico del Nord-OvestUpfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. | 2027-10-20 |
Add all 4 to your calendar (.ics) → With an account.
Among the 20 studies testing trastuzumab deruxtecan in Neoplasm Metastasis, from their registry updates:
Among AstraZeneca’s 60 in Neoplasm Metastasis:
This tab as a report to print or save as PDF → With an account.
This is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology. The target population are patients who have progressed following prior treatment or who have no satisfactory alternative treatment options, including approved second line therapies in the specific tumor type. Pre-specified HER2 mutations will be locally assessed using NGS tests or alternative methods. Prior HER2 targeting therapy is permitted.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
T-DXd monotherapy
Drug: Trastuzumab deruxtecan
Trastuzumab deruxtecan (T-DXd) by intravenous infusion
Also known as: DS-8201a (T-DXd)
Confirmed Overall Response Rate (ORR) as Per RECIST v1.1 Using Independent Central Review (ICR)
Confirmed ORR was defined as the percentage of participants who had a confirmed complete response (CR) or partial response (PR), as determined by ICR per RECIST v1.1. A CR was defined as disappearance of all target lesions (TLs) and PR was defined as at least a 30% decrease in the sum of the diameters (dms) of TL, taking as reference the baseline sum of diameters as long as criteria for PD were not met. An ICR of all radiological imaging data was carried out using RECIST v1.1. All images were collected centrally. The imaging scans were reviewed by 2 independent radiologists and were adjudicated, if required.
Time frame: Tumor scans performed at screening,then every 6 weeks (q6w) +/- 1 week relative to date of first treatment administration until RECIST v1.1 objective PD, withdrawal of consent, or death by any cause, up to DCO date of 25 Jan 2023 (approximately 24 months)
Duration of Response (DoR) as Per RECIST v1.1 Using ICR and Investigator Assessment
DoR was defined as the time from the date of first documented response until date of documented progression or death in the absence of disease progression (date of progression-free survival \[PFS\] event or censoring - date of first response + 1). The DoR was calculated using Kaplan-Meier technique.
Time frame: Tumor scans performed at screening, then q6w +/- 1 week relative to the date of first treatment administration until RECIST v1.1 objective PD, withdrawal of consent, or death by any cause, up to DCO date of 25 Jan 2023 (approximately 24 months)
Disease Control Rate (DCR) as Per RECIST v1.1 Using ICR and Investigator Assessment
DCR at 6 weeks was defined as the percentage of participants who had the best objective response (BoR) of confirmed CR or PR, or who had stable disease (SD) (without subsequent cancer therapy), for at least 5 weeks after first dose of study treatment. DCR at 12 weeks was defined as the percentage of patients who had the BoR of confirmed CR or PR, or who had SD (without subsequent cancer therapy), for at least 11 weeks after first dose of study treatment. CR was defined as disappearance of all TL and PR was defined as at least a 30% decrease in sum of the dms of TL, taking as reference the baseline sum of dms as long as criteria for PD were not met. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD (\>=20% increase in sum of dms of TLs and an absolute increase of \>=5 millimeters, taking as reference smallest sum of dms since treatment started including baseline sum of dms). CI was calculated using Clopper-Pearson method.
Time frame: Tumor scans performed at screening, then q6w +/- 1 week relative to the date of first treatment administration until RECIST v1.1 objective PD, withdrawal of consent, or death by any cause, up to DCO date of 25 Jan 2023 (approximately 24 months)
PFS as Per RECIST v1.1 Using ICR and Investigator Assessment
PFS was defined as the time from first dose of study treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from assigned therapy or received another anti-cancer therapy prior to progression (i.e. date of PFS event or censoring - date of first dose + 1). PFS was calculated using the Kaplan-Meier technique. CI for median PFS derived based on the Brookmeyer-Crowley method.
Time frame: Tumor scans performed at screening, then q6w +/- 1 week relative to the date of first treatment administration until RECIST v1.1 objective PD or death by any cause, up to DCO date of 25 Jan 2023 (approximately 24 months)
Percentage of Participants Alive and Progression-Free at 6 and 12 Months as Per RECIST v1.1 Using ICR and Investigator Assessment
Percentage of participants alive and progression-free at 6 and 12 months are reported. It was calculated using the Kaplan-Meier technique. CI for median PFS derived based on the Brookmeyer-Crowley method.
Time frame: At Months 6 and 12
Confirmed ORR as Per RECIST v1.1 Using Investigator Assessment
Confirmed ORR was defined as the percentage of participants who had a confirmed CR or PR as determined by investigator per RECIST v1.1. A CR was defined as disappearance of all TLs and PR was defined as \>=30% decrease in the sum of the dms of TL, taking as reference the baseline sum of dms as long as criteria for PD were not met.
Time frame: Tumor scans performed at screening, then q6w +/- 1 week relative to the date of first treatment administration until RECIST v1.1 objective PD, withdrawal of consent, or death by any cause, up to DCO date of 25 Jan 2023 (approximately 24 months)
Overall Survival (OS)
OS was defined as the time from the date of first dose of study treatment administration until death due to any cause regardless of whether the patient withdrew from therapy or received another anti-cancer therapy (i.e. date of death or censoring - date of first dose + 1). OS was calculated using the Kaplan-Meier technique. CI for median OS derived based on the Brookmeyer-Crowley method.
Time frame: From the date of first treatment administration up to death, approximately 24 months
Percentage of Participants Alive at 6 and 12 Months
Percentage of participants alive at 6 and 12 months are reported. It was calculated using the Kaplan-Meier technique. CI for median PFS derived based on the Brookmeyer-Crowley method.
Time frame: At Months 6 and 12
Serum Concentrations of T-DXd and Total Anti-HER2 Antibody
Serum samples were collected at specified timepoints to determine serum concentrations of T-DXd and total anti-HER2 antibody.
Time frame: Pre-infusion and 15 minutes post-infusion in Cycles 1, 2 and 4 and 5 hours post-infusion in Cycle 1 (each cycle 21 days)
Serum Concentrations of Deruxtecan (MAAA-1181a)
Serum samples were collected at specified timepoints to determine serum concentrations of MAAA-1181a.
Time frame: Pre-infusion and 15 minutes post-infusion in Cycles 1, 2 and 4 and 5 hours post-infusion in Cycle 1 (each cycle 21 days)
Percentage of Participants With Anti-Drug Antibodies (ADA) to T-DXd
Blood samples were collected to evaluate the presence of ADAs for T-DXd using validated assays. ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. ADA incidence was defined as the percentage of participants who were evaluable for ADA and were treatment-emergent ADA-positive. Treatment-emergent ADA was defined as either treatment-induced (baseline ADA negative, post-baseline ADA positive) or treatment-boosted ADA. Treatment-boosted ADA was defined as baseline positive ADA titer that was boosted to \>=2 fold during the study period. Persistently positive was defined as \>=2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive was defined as having \>=1 post baseline ADA positive measurement and not fulfilling the conditions for persistently positive.
Time frame: Up to approximately 24 months
This Phase II multicenter, open-label study was conducted in participants with unresectable and/or metastatic solid tumors harboring human epidermal growth factor receptor 2 (HER2) activating mutations regardless of tumor histology at 29 investigational sites in 9 countries. First participant was enrolled on 30 Dec 2020, last participant was enrolled on 24 May 2022 and data cut-off (DCO) date was 25 Jan 2023.
| Milestone | Trastuzumab Deruxtecan (T-DXd) |
|---|---|
| Started | 102 |
| Completed | 33 |
| Not completed | 69 |
| Withdrew: Withdrawal by subject | 8 |
| Withdrew: Lost to follow-up | 6 |
| Withdrew: Death | 55 |
Confirmed ORR was defined as the percentage of participants who had a confirmed complete response (CR) or partial response (PR), as determined by ICR per RECIST v1.1. A CR was defined as disappearance of all target lesions (TLs) and PR was defined as at least a 30% decrease in the sum of the diameters (dms) of TL, taking as reference the baseline sum of diameters as long as criteria for PD were not met. An ICR of all radiological imaging data was carried out using RECIST v1.1. All images were collected centrally. The imaging scans were reviewed by 2 independent radiologists and were adjudicated, if required.
| percentage of participants | T-DXd |
|---|---|
| Confirmed Overall Response Rate (ORR) as Per RECIST v1.1 Using Independent Central Review (ICR) | 29.4 (20.8 to 39.3) |
DoR was defined as the time from the date of first documented response until date of documented progression or death in the absence of disease progression (date of progression-free survival \[PFS\] event or censoring - date of first response + 1). The DoR was calculated using Kaplan-Meier technique.
| months | T-DXd |
|---|---|
| DoR by ICR | NA (6.8 to NA) |
| DoR by Investigator assessment | 11.0 (6.9 to 18.1) |
DCR at 6 weeks was defined as the percentage of participants who had the best objective response (BoR) of confirmed CR or PR, or who had stable disease (SD) (without subsequent cancer therapy), for at least 5 weeks after first dose of study treatment. DCR at 12 weeks was defined as the percentage of patients who had the BoR of confirmed CR or PR, or who had SD (without subsequent cancer therapy), for at least 11 weeks after first dose of study treatment. CR was defined as disappearance of all TL and PR was defined as at least a 30% decrease in sum of the dms of TL, taking as reference the baseline sum of dms as long as criteria for PD were not met. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD (\>=20% increase in sum of dms of TLs and an absolute increase of \>=5 millimeters, taking as reference smallest sum of dms since treatment started including baseline sum of dms). CI was calculated using Clopper-Pearson method.
| percentage of participants | T-DXd |
|---|---|
| DCR at 6 weeks by ICR | 75.5 (66.0 to 83.5) |
| DCR at 6 weeks by Investigator assessment | 70.6 (60.7 to 79.2) |
| DCR at 12 weeks by ICR | 53.9 (43.8 to 63.8) |
| DCR at 12 weeks by Investigator assessment | 55.9 (45.7 to 65.7) |
PFS was defined as the time from first dose of study treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from assigned therapy or received another anti-cancer therapy prior to progression (i.e. date of PFS event or censoring - date of first dose + 1). PFS was calculated using the Kaplan-Meier technique. CI for median PFS derived based on the Brookmeyer-Crowley method.
| months | T-DXd |
|---|---|
| PFS by ICR | 5.4 (2.7 to 7.1) |
| PFS by Investigator assessment | 4.4 (2.8 to 5.6) |
Percentage of participants alive and progression-free at 6 and 12 months are reported. It was calculated using the Kaplan-Meier technique. CI for median PFS derived based on the Brookmeyer-Crowley method.
| percentage of participants | T-DXd |
|---|---|
| PFS rate at 6 months by ICR | 41.4 (30.8 to 51.6) |
| PFS rate at 6 months by Investigator assessment | 37.7 (28.1 to 47.2) |
| PFS rate at 12 months by ICR | 30.9 (20.6 to 41.8) |
| PFS rate at 12 months by Investigator assessment | 26.5 (17.2 to 36.7) |
Confirmed ORR was defined as the percentage of participants who had a confirmed CR or PR as determined by investigator per RECIST v1.1. A CR was defined as disappearance of all TLs and PR was defined as \>=30% decrease in the sum of the dms of TL, taking as reference the baseline sum of dms as long as criteria for PD were not met.
| percentage of participants | T-DXd |
|---|---|
| Confirmed ORR as Per RECIST v1.1 Using Investigator Assessment | 32.4 (23.4 to 42.3) |
OS was defined as the time from the date of first dose of study treatment administration until death due to any cause regardless of whether the patient withdrew from therapy or received another anti-cancer therapy (i.e. date of death or censoring - date of first dose + 1). OS was calculated using the Kaplan-Meier technique. CI for median OS derived based on the Brookmeyer-Crowley method.
| months | T-DXd |
|---|---|
| Overall Survival (OS) | 10.9 (8.3 to 14.9) |
Percentage of participants alive at 6 and 12 months are reported. It was calculated using the Kaplan-Meier technique. CI for median PFS derived based on the Brookmeyer-Crowley method.
| percentage of participants | T-DXd |
|---|---|
| Survival rate at 6 months | 67.6 (57.4 to 75.9) |
| Survival rate at 12 months | 46.3 (35.7 to 56.3) |
Serum samples were collected at specified timepoints to determine serum concentrations of T-DXd and total anti-HER2 antibody.
| microgram/milliliter (mL) | T-DXd |
|---|---|
| T-DXd: Cycle 1: Pre-infusion | NA ± NA |
| T-DXd: Cycle 1: 15 minutes post-infusion | 116.5 ± 50.8 |
| T-DXd: Cycle 1: 5 hours post-infusion | 115.4 ± 30.5 |
| T-DXd: Cycle 2: Pre-infusion | 11.2 ± 74.1 |
| T-DXd: Cycle 2: 15 minutes post-infusion | 132.2 ± 101.5 |
| T-DXd: Cycle 4: Pre-infusion | 7.7 ± 9.1 |
| T-DXd: Cycle 4: 15 minutes post-infusion | 121.7 ± 40.1 |
| Total anti-HER2 antibody: Cycle 1: Pre-infusion | NA ± NA |
| Total anti-HER2 antibody: Cycle 1: 15 minutes post-infusion | 123.8 ± 52.8 |
| Total anti-HER2 antibody: Cycle 1: 5 hours post-infusion | 122.1 ± 42.1 |
| Total anti-HER2 antibody: Cycle 2: Pre-infusion | 6.2 ± 12.4 |
| Total anti-HER2 antibody: Cycle 2: 15 minutes post-infusion | 144.4 ± 115.4 |
| Total anti-HER2 antibody: Cycle 4: Pre-infusion | 9.9 ± 5.7 |
| Total anti-HER2 antibody: Cycle 4: 15 minutes post-infusion | 122.1 ± 37.3 |
Serum samples were collected at specified timepoints to determine serum concentrations of MAAA-1181a.
| ng/mL | T-DXd |
|---|---|
| MAAA-1181a: Cycle 1: 15 minutes post-infusion | 4.7 ± 2.9 |
| MAAA-1181a: Cycle 1: 5 hours post-infusion | 10.5 ± 5.1 |
| MAAA-1181a: Cycle 2: Pre-infusion | 0.2 ± 0.1 |
| MAAA-1181a: Cycle 2: 15 minutes post-infusion | 2.2 ± 1.5 |
| MAAA-1181a: Cycle 4: Pre-infusion | 0.3 ± 0.2 |
| MAAA-1181a: Cycle 4: 15 minutes post-infusion | 1.5 ± 0.9 |
Blood samples were collected to evaluate the presence of ADAs for T-DXd using validated assays. ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. ADA incidence was defined as the percentage of participants who were evaluable for ADA and were treatment-emergent ADA-positive. Treatment-emergent ADA was defined as either treatment-induced (baseline ADA negative, post-baseline ADA positive) or treatment-boosted ADA. Treatment-boosted ADA was defined as baseline positive ADA titer that was boosted to \>=2 fold during the study period. Persistently positive was defined as \>=2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive was defined as having \>=1 post baseline ADA positive measurement and not fulfilling the conditions for persistently positive.
| percentage of participants | T-DXd |
|---|---|
| ADA positive at any visit (ADA prevalence) | 2.1 |
| ADA incidence | 0 |
| Treatment-emergent ADA positive | 0 |
| Treatment-boosted ADA positive | 0 |
| Persistently positive ADA | 0 |
| Transiently positive ADA | 0 |
Collected over Treatment-emergent adverse events were collected from start of first dose of study treatment up to and including 47 days following the date of last dose of study treatment or before the initiation of first subsequent anti-cancer therapy following discontinuation of study treatment (whichever occurred first), up to DCO date of 25 Jan 2023 (approximately 24 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| T-DXd | 58/102 (56.9%) | 36/102 (35.3%) | 96/102 (94.1%) |
| Event | T-DXd |
|---|---|
| PneumonitisRespiratory, thoracic and mediastinal disorders | 4/102 |
| Bone painMusculoskeletal and connective tissue disorders | 2/102 |
| Acute kidney injuryRenal and urinary disorders | 2/102 |
| AnaemiaBlood and lymphatic system disorders | 2/102 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/102 |
| ConstipationGastrointestinal disorders | 2/102 |
| VomitingGastrointestinal disorders | 2/102 |
| AstheniaGeneral disorders | 2/102 |
| CholangitisHepatobiliary disorders | 2/102 |
| Biliary tract infectionInfections and infestations | 2/102 |
| Event | T-DXd |
|---|---|
| NauseaGastrointestinal disorders | 49/102 |
| AnaemiaBlood and lymphatic system disorders | 35/102 |
| FatigueGeneral disorders | 31/102 |
| DiarrhoeaGastrointestinal disorders | 28/102 |
| Decreased appetiteMetabolism and nutrition disorders | 24/102 |
| AstheniaGeneral disorders | 19/102 |
| Aspartate aminotransferase increasedInvestigations | 18/102 |
| AlopeciaSkin and subcutaneous tissue disorders | 18/102 |
| ConstipationGastrointestinal disorders | 18/102 |
| Neutrophil count decreasedInvestigations | 15/102 |
The Full Analysis Set (FAS) consisted of all participants who received at least 1 dose of study treatment.
| Age, Continuous(years) | T-DXd |
|---|---|
| Mean | 64.2 ± 10.29 |
| Sex: Female, Male(Participants) | T-DXd |
|---|---|
| Female | 62 |
| Male | 40 |
| Ethnicity (NIH/OMB)(Participants) | T-DXd |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 91 |
| Unknown or Not Reported | 9 |
| Race (NIH/OMB)(Participants) | T-DXd |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 38 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 51 |
| More than one race | 0 |
| Unknown or Not Reported | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Dec 2020 to primary completion in Jan 2023, 24 months.
Results were first posted in Feb 2024, 1 year after primary completion.
Of 88 industry-sponsored phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 63. This study's 24 months is below that.
Counting every sponsor, half of 443 studies reached it within 56 months; a quarter within 33 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab deruxtecan